Early Diagnosis Of Childhood Cerebral ALD

Adrenoleukodystrophy Clinical Trial

Official title:

Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02948062
• Other study ID #: 2016NTLS155
• Secondary ID: MT2016-29R
• Status: Withdrawn
• Start date: November 2018
• Est. completion date: July 2023

Study information

• Verified date: July 2018
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this single institution study is to evaluate boys with adrenoleukodystrophy (ALD) diagnosed early in life, and to prospectively monitor them to determine parameters that will facilitate earlier detection of the childhood cerebral form of the disease. These at-risk subjects will be assessed yearly through travel to the University of Minnesota, where plasma and cerebral spinal fluid (CSF) biomarker studies, MRI based imaging and neuropsychological assessments will be performed at the University of Minnesota Masonic Children's Hospital and Clinics. The MRI and lumbar puncture to obtain CSF will be obtained under sedation. In addition, at intervening 6 months intervals information will be obtained remotely, including surveys and MRI's in their home location. Also at that time blood samples will be obtained locally and shipped to the University of Minnesota for study. There is no therapeutic intent in this study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2023
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 1 Year to 5 Years

Eligibility

Inclusion Criteria:

• Boys with confirmed adrenoleukodystrophy, as determined by very long chain fatty acid (VLCFA) analysis and/or genotyping. Genotyping is not necessary for diagnosis.

• Between 1 and 5 years of age, inclusive at the time of consent.

• Able to undergo a sedation

• English as primary language of the household, to maximize consistency of the neuropsychological/developmental testing.

• Voluntary written parental/guardian consent

Exclusion Criteria:

• Evidence of cerebral disease at time of enrollment - patients over 3 years of age must have an MRI within 4 months of signing consent to confirm that there is no evidence of cerebral disease

• Inability or unwillingness to travel to the University of Minnesota once a year for the duration of the study

• Evidence of cerebral disease by standard T2/FLAIR MRI. If a subject develops cerebral ALD during the study, they will come off study, as it is anticipated that they would be considered for transplantation.

Related Conditions & MeSH terms

• Adrenoleukodystrophy

Locations

Country	Name	City	State
United States	Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ALD Early Evaluation	To evaluate boys with adrenoleukodystrophy (ALD) diagnosed early in life, and to prospectively determine factors that have a high correlation with the emergence of cerebral ALD.	5 years
Secondary	Emergence of cerebral disease through imaging	The ability to discern the emergence of cerebral disease through imaging prior to the onset of classic T2 imaging. This will include diffusion tensor imaging (DTI), T1 and T2 rho, RAFF and spectroscopy, in addition to the standard MRI evaluations including gadolinium enhancement.	5 years
Secondary	Biomarker Study: Inflammation Markers	Markers of inflammation (chitotriosidase, lipidomics including arachidonic acid metabolites and inflammatory cytokines).	5 years
Secondary	Biomarker Study: Oxidative Stress	Determinations of oxidative stress (including but not limited to total and reduced/oxidized glutathione and 4-hydroxynonenal, or 4-HNE).	5 years
Secondary	Biomarker Study: Immunologic Activation		5 years
Secondary	Neuropsychology testing	Extensive neuropsychology testing, including assessments of verbal comprehension, perceptual reasoning, working memory and processing speed.	5 years